Diaceutics (DXRX) Price & Analysis

Compare

10 Followers

DXRX Stock Chart & Stats

161.50p

0.50p(0.34%)

At close: Jan 09 4:00 PM EST

161.50p

0.50p(0.34%)

Day’s Range― - ―

52-Week Range106.00p - 176.25p

Previous CloseN/A

Volume29.93K

Average Volume (3M)79.63K

Market Cap

£143.81M

Enterprise Value134.56M

Total Cash (Recent Filing)£10.38M

Total Debt (Recent Filing)£1.13M

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Mar 24, 2026

EPS Estimate

0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding84,912,440

10 Day Avg. Volume58,068

30 Day Avg. Volume79,634

Financial Highlights & Ratios

PEG Ratio25.77

Price to Book (P/B)2.66

Price to Sales (P/S)3.30

P/FCF Ratio-26.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£215.00

Price Target Upside33.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Contract NegotiationDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.

Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.

Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, and during FY24 Diaceutics worked with 85 therapies across 52 customers.

Bears Say

Share Price VolatilityAnalyst sees the recent share pullback as a buying opportunity due to the business delivering very strong organic growth and trading on just 2.3x current FY25E EV/sales, despite its superior top-line growth.

Diaceutics News

Diaceutics Returns to Profit as Recurring Revenues and Order Book Hit Record Highs

Diaceutics ( ($GB:DXRX) ) just unveiled an announcement. Diaceutics reported an estimated 20% rise in 2025 revenues to...

18d ago

Diaceutics Issues Shares to Trust Under Ongoing Incentive Plan, Updates Total Voting Rights

Diaceutics ( ($GB:DXRX) ) has issued an announcement. Diaceutics has reported that the trustees of its Global 2020...

1M ago

Diaceutics PLC Expands Employee Share Incentive Plan

Diaceutics ( ($GB:DXRX) ) has provided an update. Diaceutics PLC has announced that trustees of its 2020 Employee...

2M ago

Diaceutics PLC Enhances Employee Engagement with Share Incentive Plan

Diaceutics ( ($GB:DXRX) ) has shared an update. Diaceutics PLC has announced that its trustees have purchased ordinary...

3M ago

Diaceutics Enhances Employee Incentives with Share Purchases

Diaceutics ( ($GB:DXRX) ) has issued an announcement. Diaceutics PLC has announced the purchase of ordinary shares by...

4M ago

Diaceutics Plc Reports Strong H1 2025 Performance

Diaceutics Plc ( ($DIUXF) ) has released its Q2 earnings. Here is a breakdown of the information Diaceutics...

4M ago

Diaceutics PLC Reports Strong H1 2025 Results, On Track for Profitability

Diaceutics ( ($GB:DXRX) ) has shared an announcement. Diaceutics PLC reported strong financial results for the first half...

4M ago

Diaceutics to Announce Half-Year Results and Host Investor Webinar

Diaceutics ( ($GB:DXRX) ) has provided an update. Diaceutics PLC announced it will release its unaudited half-year results...

5M ago

Diaceutics PLC Expands Share Incentive Plan with New Share Issuance

Diaceutics ( ($GB:DXRX) ) just unveiled an announcement. Diaceutics PLC has announced that Global Shares Trustees (UK) Limited...

5M ago

Diaceutics to Present at Canaccord Genuity Growth Conference

Diaceutics ( ($GB:DXRX) ) has issued an update. Diaceutics PLC announced its participation in the Canaccord Genuity 45th...

6M ago

Diaceutics price target raised to 195 GBp from 165 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165...

12M ago

Diaceutics price target raised to 165 GBp from 145 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics to 165 GBp from 145 GBp...

2y ago

DXRX FAQ

What was Diaceutics’s price range in the past 12 months?

Diaceutics lowest share price was 106.00p and its highest was 176.25p in the past 12 months.

What is Diaceutics’s market cap?

Diaceutics’s market cap is £143.81M.

When is Diaceutics’s upcoming earnings report date?

Diaceutics’s upcoming earnings report date is Mar 24, 2026 which is in 50 days.

How were Diaceutics’s earnings last quarter?

Diaceutics released its earnings results on Sep 23, 2025. The company reported -0.028p earnings per share for the quarter, the consensus estimate of -0.028p by 0p.

Is Diaceutics overvalued?

According to Wall Street analysts Diaceutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Diaceutics pay dividends?

Diaceutics does not currently pay dividends.

What is Diaceutics’s EPS estimate?

Diaceutics’s EPS estimate is 0.03.

How many shares outstanding does Diaceutics have?

Diaceutics has 84,912,440 shares outstanding.

What happened to Diaceutics’s price movement after its last earnings report?

Diaceutics reported an EPS of -0.028p in its last earnings report, expectations of -0.028p. Following the earnings report the stock price went up 4.605%.

Which hedge fund is a major shareholder of Diaceutics?

Currently, no hedge funds are holding shares in GB:DXRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Diaceutics

Diaceutics (DXRX) is a data analytics and technology company specializing in precision medicine and diagnostics. The company operates primarily in the healthcare sector, providing solutions that enhance the development and commercialization of targeted therapies. Diaceutics offers a comprehensive platform that integrates diagnostic data, patient insights, and real-world evidence, enabling pharmaceutical companies to optimize their strategies in personalized medicine, improve patient outcomes, and streamline the diagnostic journey.

Diaceutics (DXRX) Earnings & Revenues

Historic Earnings Reports

DXRX Stock 12 Month Forecast

Average Price Target

215.00p

▲(33.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"115p","216":"216p","140.25":"140.3p","165.5":"165.5p","190.75":"190.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">215.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">215.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">215.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,140.25,165.5,190.75,216],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,173.46153846153845,176.92307692307693,180.3846153846154,183.84615384615384,187.30769230769232,190.76923076923077,194.23076923076923,197.69230769230768,201.15384615384616,204.6153846153846,208.0769230769231,211.53846153846155,{"y":215,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,173.46153846153845,176.92307692307693,180.3846153846154,183.84615384615384,187.30769230769232,190.76923076923077,194.23076923076923,197.69230769230768,201.15384615384616,204.6153846153846,208.0769230769231,211.53846153846155,{"y":215,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,173.46153846153845,176.92307692307693,180.3846153846154,183.84615384615384,187.30769230769232,190.76923076923077,194.23076923076923,197.69230769230768,201.15384615384616,204.6153846153846,208.0769230769231,211.53846153846155,{"y":215,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":136,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.5,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":128,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >